BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Charles River Laboratories Completes Acquisition of HemaCare for $380 Million Cash
Charles River Acquires Hemacare

Charles River Laboratories Completes Acquisition of HemaCare for $380 Million Cash

January 10, 2020 By Cade Hildreth (CEO) Leave a Comment

Charles River Laboratories (NYSE: CRL) has completed its acquisition of HemaCare Corporation (OTCMKTS: HEMA) for $380 million in cash, or $25.40 per HemaCare share.

Discover class-defining bioproduction tools.

Acquiring HemaCare has several strategic purposes for Charles River, including:

  1. Expands Charles River’s scientific capabilities in the emerging, high-growth cell therapy sector.
  2. Creates a portfolio of early-stage research and manufacturing support solutions to help cell therapy developers and manufacturers from early-stage development to commercialization.
  3. Creates anticipated revenue growth for Charles River, with the company estimating revenue growth of at least 30% annually over the next five years.

Why Hemacare as an Acquisition Target?

Charles River Labs acquires HemacareHeadquartered near Los Angeles, California, HemaCare Corporation (OTCMKTS: HEMA) is a leader in the customization and supply of human-derived biological products and services for biomedical research and cell therapy.

Within the U.S. and internationally, the company is well-known for its network of FDA-registered, GMP/GTP-compliant collection centers where it collects human biological materials.

bitbio

Types of cellular materials collected and supplied by Hemacare include peripheral blood, bone marrow, and cord blood, each of which it isolates into primary cells types and can supply to customers in both fresh and frozen states.

Furthermore, Hemacare is the provider of leukapheresis process development material for the following FDA-approved immunocellular therapies, making it a powerful target for acquisition:

Pluristyx
  • Kymriah® (Novartis; Switzerland)
  • Yescarta® (Kite, a Gilead Company; CA, USA)
  • Provenge® (Dendreon; WA, USA).

To learn about about the acquisition, view the press announcement here.

Do you have question about this acquisition? Ask them in the comments below.

5/5 - (3 votes)

Filed Under: Cell Therapy, Stem Cell News Tagged With: acquisition

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Featured Posts

Cord Blood Market Segmentation

Cord Blood Market Segmentation – Biobanking, HSCT, Cellular Therapy, Genetic Manipulation, & Research Tools

CAR-T Companies

CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.